TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04162197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GEO
Description: Robot-Assisted Gait Training (RAGT) The Robotic Group (RG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GEO and HUNOVA
Description: Robot-Assisted Gait Training (RAGT) and Balance Training. The Balance Group (GHG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland) and a Balance training using a robotic proprioceptive platform (Hunova - Movendo Technology, Italy).
Study: NCT04315272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD\&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03730181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine
Description: Rifapentine. Initial dose will be 25mg/kg. Based on interim analysis, this may be adjusted throughout the study to achieve target exposures. The standalone water-dispersible rifapentine tablet may be used to adjust the rifapentine doses, if needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid. 25mg/kg
Study: NCT03004508

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gingko Biloba Extract
Description: 120mg/day, twice a day, 6 month

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 120mg/day, twice a day, 6 month
Study: NCT05889039

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BEMER
Description: Bio-Electro-Magnetic Energy Regulation (BEMER) is an emerging therapeutic modality that deploys a biorhythmically defined stimulus through a pulsed electromagnetic field and has been shown to reduce musculoskeletal pain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BEMER
Description: Bio-Electro-Magnetic Energy Regulation (BEMER) is an emerging therapeutic modality that deploys a biorhythmically defined stimulus through a pulsed electromagnetic field and has been shown to reduce musculoskeletal pain.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OMT
Description: Osteopathic manipulative therapy (OMT) is a form of manual therapy utilized by osteopathic physicians and some allopathic physicians to treat a broad variety of musculoskeletal ailments, including neck pain.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OMT
Description: Osteopathic manipulative therapy (OMT) is a form of manual therapy utilized by osteopathic physicians and some allopathic physicians to treat a broad variety of musculoskeletal ailments, including neck pain.
Study: NCT04088656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systems Analysis and Improvement Approach for Hypertension Screening and Treatment Optimization
Description: The Systems Analysis and Improvement Approach to Optimize the Hypertension Care Cascade for People Living with HIV (SAIA-HTN) is a five-step systems analysis and iterative improvement cycle intervention which will be implemented by study nurses and district managers in intervention facilities. Components of the intervention include joint care cascade analysis, patient flow mapping and continuous quality improvement, aimed to incrementally improve hypertension screening, diagnosis, treatment and care in the HIV+ population at intervention health facilities.
Study: NCT02791399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ISOP Intervention with the Nurse Care Manager
Description: A Nurse Care Manager (NCM) will maintain a registry of enrolled patients, track opioid medication-related events from the medical record, and provide decision support to Primary Care Providers for issues related to prescription opioid safety. The NCM will also meet individually with enrolled participants in the intervention group to discuss strategies for preventing/reducing opioid side effects, preventing diversion, and providing rationale for screening for prescription opioid misuse.
Study: NCT02158260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Position changing
Study: NCT04407260

Intervention type: DEVICE
Intervention: Oxygen Hood
Description: High-Flow Oxygen Hood with neck dam and intake and exhaust tubing incorporating a Bacterial/Viral HEPA filter and optional PEEP attachment.
Study: NCT01994590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Starting dose will be 400 mg by mouth daily on Days 1-5, 8-12, 15-19, and 22-26 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 4 tablets (250 mg each) by mouth daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg by mouth twice daily.
Study: NCT04078178

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niagen
Description: Nicotinamide Riboside

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niagen
Description: Nicotinamide Riboside

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Comparator
Description: Placebo
Study: NCT03376100

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided nerve blocks
Description: Ultrasound guided nerve blocks of the radial and median nerves

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hematoma Block
Description: Conventional local anesthetic method using hematoma block
Study: NCT02394678

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AngioJet Thrombectomy System
Description: Mechanical removal of blood, using a pressurised jet of water, from ventricles of patients suffering from intraventricular haemorrhage
Study: NCT00426231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation by a health worker
Description: Help provided by health worker to navigate medication access programs

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information control
Description: Information about medication access programs provided to the participant and their healthcare provider
Study: NCT04259554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFC rTMS
Description: repetitive transcranial magnetic stimulation over right orbito-frontal cortex with 1Hz (360 pulses in 6 trains á 60 pulses with 30s intertrain-interval)
Study: NCT04177927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capnostream 20p / Coviden
Description: The special nasal canule is used for detection carbondioxide from breathe of patients

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rutine monitoring
Description: peripheric Oxygen saturation is monitored.
Study: NCT03577470

Intervention type: DRUG
Intervention: D/C/F/TAF Fixed-Dose Combination (FDC)
Description: Participants in treatment with D/C/F/TAF FDC, coming from different treatment histories will be observed in this study. No interventions will be administered as a part of this study.

Intervention type: DRUG
Intervention: D/C/F/TAF Fixed-Dose Combination (FDC)
Description: Participants in treatment with D/C/F/TAF FDC, coming from different treatment histories will be observed in this study. No interventions will be administered as a part of this study.

Intervention type: DRUG
Intervention: D/C/F/TAF Fixed-Dose Combination (FDC)
Description: Participants in treatment with D/C/F/TAF FDC, coming from different treatment histories will be observed in this study. No interventions will be administered as a part of this study.
Study: NCT06712381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Carac (fluorouracil) Cream, 0.5% is used by adults to treat skin conditions on the face and front part of the scalp called solar keratosis or actinic keratosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy
Description: Photodynamic therapy (PDT) is a procedure that uses a photosensitizing drug to apply light therapy selectively to target pre-skin cancer, acne and sun damage.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carac in combination with PDT
Study: NCT06711445

Intervention type: OTHER
Intervention: Tele-assessment
Description: The participants were evaluated in two settings on different days (24-48 h apart): (i) in clinical settings (face-to-face) and (ii) at home via 'WhatsApp' phone application (both asynchronized and synchronized tele-assessment).~The evaluations steps were as follows:~1. Face-to-face/ Clinic assessment: Rater 1 completed all clinical assessments.~2. Synchronized tele-assessment: Rater 1 repeated the same evaluations via video calls to the patients (these were recorded to be used in step 3).~3. Asynchronized tele-assessment: Rater 2 evaluated the recordings of the remote evaluations (made in step 2).~4. Retest of synchronized tele-assessment: Rater 1 evaluated patients via video calls (these were recorded to be used in step 5).~5. Retest of asynchronized tele-assessment: Rater 2 evaluated the recordings of the remote evaluations (made in step 4).
Study: NCT05267977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalosporin 1St Generation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalosporin 1St Generation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminoglycosides
Study: NCT01590069

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aerosolized Aldesleukin
Description: Breathe aerosolized aldesleukin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study: NCT05889039

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham OMT + Sham BEMER
Description: Participants in the CONTROL group received light touch and BEMER sham treatments. Researchers placed their hands lightly on the subject's cervical paraspinal muscles in the supine position and on the upper thoracic paraspinal muscles in the prone position for approximately 5 minutes. This was done to mimic myofascial release techniques; however, no pressure or action was done. In addition, the subject's laid supine on the BEMER mat (as they would do during a BEMER session), but the device was not activated.
Study: NCT00002727

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00605150

Intervention type: RADIATION
Intervention: TheraSphere-Yttrium 90 microsphere
Description: TheraSphere is delivered to the liver via a catheter placed into the femoral artery and guided by fluoroscopy to the hepatic artery. Once the catheter is properly positioned, the physician infuses TheraSphere, which localizes preferentially in the tumor.
Study: NCT03729557

Intervention type: PROCEDURE
Intervention: Nephrectomy
Description: Unilateral nephrectomy
Study: NCT00006942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04513327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation using Digital Healthcare System (Uincare Homeplus)
Description: Uincare Homeplus is a device using infrared, kinect camera and motion capture technology to track 3D motion of the patients' posture and joint articulations. It also has embedded exercise training software dedicated to anterior cruciate ligament reconstruction post-op rehabilitation at home.~Home-based self-rehabilitation using brochure for 2 weeks post surgery (same as the active comparator)~Home-based self-rehabilitation using digital healthcare system(Uincare Homeplus) for 2 to 12 weeks post surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: Home-based self-rehabilitation using brochure for 12 weeks post surgery.
Study: NCT03526562

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise according to dose escalation
Study: NCT03157349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofreeze
Description: Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied 10 minutes prior to manipulation and at home for 4 times a day for 1 week

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: The placebo is the Biofreeze product with all active ingredients removed. The product will be applied 10 minutes prior to manipulation and at home for 4 times a day for 1 week
Study: NCT00571480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: ear acupuncture needles will be inserted into three preselected acupuncture points which are thought to be specific for low back pain

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: ear acupuncture needles are inserted into three preselected acupuncture points which are thought not specific to low back pain

Intervention type: OTHER
Group type: OTHER
Intervention: standard of care
Description: participants can take acetaminophen 650 mg no more than every 6 hours and frequent rest and topical warm/cold compress
Study: NCT06401941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: HBO session includes three 20-minute inhalations of pure oxygen in a hyperbaric chamber utilizing specially fitted face masks for each patient. The session is conducted as follows: 10 minutes compression of up to 2.5 atm (0.25 MPa), inhalation of 100% oxygen for 20 minutes, a 5-minute break in the chamber without the mask (oxygen concentration up to 23%, constant temperature (room) and humidity), again 20 minutes inhalation of 100% oxygen, another 5-minute break (the same condition), the last 20 minutes inhalation of 100% oxygen, and finally a 10-minute decompression. The total duration of the session was 90 minutes.
Study: NCT02743221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil + bevacizumab
Description: Patients were treated withTrifluridine/tipiracil + bevacizumab regimen until they met a discontinuation criterion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine + bevacizumab
Description: Patients were treated with capecitabine+ bevacizumab regimen until they met a discontinuation criterion.
Study: NCT03228732

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: There will be two 2-day inpatient visits with 8-weeks of treatment with placebo between those visits.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: There will be two 2-day inpatient visits with 8-weeks of treatment with placebo between those visits.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine between those visits.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DHEA
Description: There will be two 2-day inpatient visits with 8-weeks of treatment with DHEA between those visits.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine and DHEA
Description: There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine and DHEA between those visits.
Study: NCT01655680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: ABT-126 Middle Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: ABT-126 Low Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: ABT-126 High Dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04450836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib then Trifluridine/Tipiracil
Description: REGORAFENIB 160 mg per day during 3 weeks followed by 1 week off of each 4-week cycle except for cycle 1.~During first cycle: dose is started at 80 mg per day at week 1, 120 mg per day at week 2, 160 mg per day at week 3, followed by 1 week off.~Then TRIFLURIDINE/TIPIRACIL 35 mg/m² Dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 4-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil then Regorafenib
Description: TRIFLURIDINE/TIPIRACIL 35 mg/m² Dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 4-week cycle.~Then REGORAFENIB 160 mg per day during 3 weeks followed by 1 week off of each 4-week cycle except for cycle 1.~During first cycle: dose is started at 80 mg per day at week 1, 120 mg per day at week 2, 160 mg per day at week 3, followed by 1 week off.
Study: NCT00053365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irofulven
Description: Given IV
Study: NCT02260531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study: NCT02889692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YiQiFang
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YangYinFang
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YiQiYangYinFang
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo granules
Description: Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erlotinib®
Description: Erlotinib®,tarceva, 150 mg oral once a day until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib®
Description: Erlotinib®,tarceva, 150 mg oral once a day until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gefitinib®
Description: Gefitinib®,Iressa, 250 mg oral once a day until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib®
Description: Gefitinib®,Iressa, 250 mg oral once a day until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Icotinib®
Description: Icotinib®,Conmana 125 mg oral three times a day until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib®
Description: Icotinib®,Conmana 125 mg oral three times a day until progression or unacceptable toxicity develops.
Study: NCT01456507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALO-02 (Oxycodone Naltrexone)
Description: single dose of ALO-02 capsule under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALO-02 (Oxycodone Naltrexone)
Description: single dose of ALO-02 capsule under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALO-02 (Oxycodone Naltrexone)
Description: ALO-02 with the ALO-02 pellets sprinkled on applesauce, and administered under fasting conditions.
Study: NCT02119169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pigtail catheter
Description: pigtail catheter for pleural drainage
Study: NCT03092024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPIN-HAND program
Description: The internet-based SPIN-HAND program consists of 4 modules (1) Thumb Flexibility and Strength (3 exercises); (2) Finger Bending (3 exercises); (3) Finger Extension (3 exercises); and (4) Wrist Flexibility and Strength (2 exercises). The program includes sections on developing a personalized program, goal-setting strategies and examples, progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with hand disability and hand exercises. Instructional videos demonstrate and explain how to perform each exercise properly with pictures to illustrate common mistakes. Separate versions of each exercise are available for patients with mild/moderate and more severe hand involvement.
Study: NCT03150160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brinzolamide 1%/brimonidine 0.2% fixed combination
Description: One drop applied topically to the affected eye(s) in the morning and evening

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One drop applied topically to the affected eye(s) in the morning and evening
Study: NCT00731042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avagard
Description: Topical solution, 6 mL, 6 applications/day for 14 days.
Study: NCT03150160

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: travoprost 0.004% ophthalmic solution
Description: One drop applied topically to the affected eye(s) in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: travoprost 0.004% ophthalmic solution
Description: One drop applied topically to the affected eye(s) in the evening
Study: NCT00731042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Purell Surgical Scrub
Description: Topical solution, 4 mL, 6 applications/day for 14 days.